Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor

Fudan University52 enrolled

Overview

To investigate the treatment pattern and efficacy of patients with positive primary ER lesion but negative ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage. * MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2010 and 2022 * Patients diagnosed with primary ER-positive tumor and who were yet to receive any systemic therapy during the advanced stage Exclusion Criteria: * Patients with incomplete medical records and those diagnosed with secondary primary tumors

Locations (1)

Biyun Wang, MD

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Progression free survival (PFS)

Time frame: 6 weeks

Secondary Outcomes

Adverse events

Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.